近期,国内仿制药圈的“乌帕替尼缓释片”话题群像炸了锅。起因是一纸药监局通知件:复星医药旗下复星万邦(江苏)医药集团的乌帕替尼缓释片双规格仿制申请被列入“不予批准”,宣告首仿再度失利。这已是继山东齐都药业、江苏和晨药业、昂利康制药之后,第四家倒在这一靶点的药企。截图来源:NMPA一、暴涨的明星药,为何成了仿制“死亡谷”?要读懂这场四连败,就得先看清乌帕替尼缓释片的“含金量”。它是艾伯维手握的重磅口服...
Source Link近期,国内仿制药圈的“乌帕替尼缓释片”话题群像炸了锅。起因是一纸药监局通知件:复星医药旗下复星万邦(江苏)医药集团的乌帕替尼缓释片双规格仿制申请被列入“不予批准”,宣告首仿再度失利。这已是继山东齐都药业、江苏和晨药业、昂利康制药之后,第四家倒在这一靶点的药企。截图来源:NMPA一、暴涨的明星药,为何成了仿制“死亡谷”?要读懂这场四连败,就得先看清乌帕替尼缓释片的“含金量”。它是艾伯维手握的重磅口服...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.